Duke University Pratt School of Engineering Honored David Brady, PhD, Co-Founder of Centice Corporation, with an Endowed Professorship

Share Article

Centice Corporation, a pioneer in drug verification and safety products, announced today that David Brady, PhD, has been honored with an endowed professorship as the Michael J. Fitzpatrick Professor of Engineering. Dr. Brady is also co-founder and on the Board of Directors of Centice Corporation.

Centice logo

We are very proud of David being named the Michael J. Fitzpatrick Professor of Engineering; it is a terrific honor. His leadership at Duke has been exceptional as has been his work in computational optical imaging

Centice Corporation, a pioneer in drug verification and safety products, announced today that David Brady, PhD, has been honored with an endowed professorship as the Michael J. Fitzpatrick Professor of Engineering. Dr. Brady is also co-founder and on the Board of Directors of Centice Corporation.

Dr. Brady co-founded Centice in June 2004 and will maintain his role as Centice's Chief Scientist as well as remaining on its Board of Directors. Since founding Centice, Dr. Brady has played a crucial role in the development, launch and enhancements of its initial product, PASS Rx®. The PASS Rx system provides solid dose medication verification solutions to retail pharmacies, hospital pharmacies, etc. It scientifically verifies NDC barcode data on a standard prescription vial to the vial contents and easily integrates into the pharmacy workflow, providing protection from drug dispensing errors and counterfeits.

The Institute of Medicine states that 1.5 million people are harmed every year from medication errors, due to the wrong drug or strength. Confusion caused by drugs with similar names accounts for up to 25 percent of the reported errors. The PASS Rx system helps pharmacists and technicians avoid these errors, improving quality and efficiency within retail or hospital outpatient pharmacies.

"We are very proud of David being named the Michael J. Fitzpatrick Professor of Engineering; it is a terrific honor. His leadership at Duke has been exceptional as has been his work in computational optical imaging," said Scott Albert, Chairman of the Board and Chief Executive Officer of Centice.

Dr. David J. Brady leads the Duke Imaging and Spectroscopy Program in the Fitzpatrick Center. He is a pioneer of computational optical imaging and spectroscopy. Prior to joining the Duke Faculty as founding director of the Fitzpatrick Institute for Photonics, Brady was on the faculty at the University of Illinois (1990-2001). He earned a BA in physics and math from Macalester College and MS and PhD from the California Institute of Technology. He is also the Chief Scientist and Chairman of the Board of Directors at Applied Quantum Technologies, which manufactures spectral imaging systems. Brady is a fellow of OSA, SPIE and IEEE.

About Centice Corporation
Centice, founded in 2004 and headquartered in Morrisville, NC, is commercializing patented and patent-pending computational sensor and machine vision technology. The PASS Rx® pharmaceutical authentication sensor system improves the verification process for dispensed medications, thereby improving quality and optimizing workflow in the pharmacy. The company has received venture capital investments from The Aurora Funds, Inc., Novak Biddle Venture Partners, S-Group Direct Investments Ltd, Innovation Ventures LP, Fulcrum Financial Group, L.P. and other private investors. More information on Centice can be found at http://www.centice.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Stacy Stein
Centice Corporation
919-653-0424 ext. 100
Email >
Visit website